IVERIC bio (ISEE) vs. Its Peers Financial Survey

IVERIC bio (NASDAQ: ISEE) is one of 555 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare IVERIC bio to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.

Volatility & Risk

IVERIC bio has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, IVERIC bio’s competitors have a beta of 1.33, meaning that their average share price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

45.3% of IVERIC bio shares are held by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 4.3% of IVERIC bio shares are held by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for IVERIC bio and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IVERIC bio 0 0 0 0 N/A
IVERIC bio Competitors 4727 13406 28187 1020 2.54

As a group, “Pharmaceutical preparations” companies have a potential upside of 61.91%. Given IVERIC bio’s competitors higher probable upside, analysts plainly believe IVERIC bio has less favorable growth aspects than its competitors.


This table compares IVERIC bio and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IVERIC bio N/A -94.05% -44.30%
IVERIC bio Competitors -1,566.06% -828.31% -27.99%

Valuation and Earnings

This table compares IVERIC bio and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IVERIC bio $209.98 million $63.09 million -0.81
IVERIC bio Competitors $2.14 billion $224.95 million -3.93

IVERIC bio’s competitors have higher revenue and earnings than IVERIC bio. IVERIC bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


IVERIC bio competitors beat IVERIC bio on 6 of the 10 factors compared.

IVERIC bio Company Profile

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.